- £66.00bn
- £100.49bn
- $210.13bn
- 40
- 92
- 41
- 60
C2019 December 31st | C2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 159,307 | 105,944 | 157,739 | 241,392 | 210,130 |
Cost of Revenue | |||||
Gross Profit | 45,682 | 25,328 | 37,735 | 69,498 | 64,057 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 151,627 | 127,944 | 144,237 | 226,986 | 185,315 |
Operating Profit | 7,680 | -22,000 | 13,502 | 14,406 | 24,815 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 8,154 | -24,888 | 15,227 | 15,405 | 23,749 |
Provision for Income Taxes | |||||
Net Income After Taxes | 4,190 | -20,729 | 8,487 | 477 | 16,112 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Extraordinary Items | |||||
Net Income | 4,026 | -20,305 | 7,565 | -2,487 | 15,239 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 4,025 | -20,306 | 7,563 | -2,488 | 15,238 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.691 | -0.015 | 0.319 | 1.3 | 1.33 |
Dividends per Share |